ClinicalTrials.gg
CompletedNCT05375305Updated Dec 26, 2023

A Study of SHR8554 Injection for the Treatment of Pain After Orthopedic Surgery

A Phase 2/3 interventional study of SHR8554 Injection and SHR8554 Injection in Pain, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-12-26.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
320
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies in Pain by Jiangsu HengRui Medicine Co., Ltd. — none open to participants now, none under way, none of them phase 3. Pain · Jiangsu HengRui Medicine Co., Ltd..

Enrollment
2nd of 15
320 · median 96
Started
2022
with 3 others
Phase 2/3
2 of 15
none open now
Registered
9th of 15
by date

Among the 15 studies in Pain by Jiangsu HengRui Medicine Co., Ltd., this one is the 2nd largest by enrollment, is one of 4 that started in 2022, is one of 2 in phase 2/3, and was the 9th registered.

Pain

10,069 studies on the registry are indexed under Pain; 1,650 are open to participants now.

Browse Pain studies →

Open to participants now

None of the 15 studies in Pain by Jiangsu HengRui Medicine Co., Ltd. is open now. The open studies under Pain, anywhere →

Where they have run

Who these studies take

Of the 927 Pain studies recruiting now, 382 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 221 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 15 studies in Pain by Jiangsu HengRui Medicine Co., Ltd. as a file.
02

Study summary

The primary objective is to evaluate the analgesic efficacy of IV SHR8554 compared with morphine and placebo in patients with acute postoperative pain following orthopedic surgery.

03

Conditions studied

  • Pain

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Able and willing to provide a written
  2. Subjects requiring elective general anesthesia orthopedic surgery
  3. Conform to the ASA Physical Status Classification

Exclusion criteria

Exclusion Criteria:

  1. Subjects with a history of difficult airway
  2. Subjects with a history of reflux esophagitis
  3. Subjects with a history of mental illness
  4. Subjects with poor blood pressure control
  5. Transcutaneous oxygen saturation (SpO2) \<90%
  6. Random blood glucose ≥11.1mmol/L
  7. Subjects with abnormal liver function
  8. allergies to opioids and other medications that may be used during the trial
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
320 participants (actual)

Study arms

  • Experimental
    Treatment group A:SHR8554 Injection

    Drug: SHR8554 Injection

  • Experimental
    Treatment group B:SHR8554 Injection

    Drug: SHR8554 Injection

  • Placebo comparator
    Treatment group C:Saline Solution

    Drug: Saline Solution

  • Active comparator
    Treatment group D:Morphine

    Drug: Morphine

Interventions

06

What researchers measure

Primary outcomes

  1. the Sum of Pain Intensity Differences in Pain Score Over 48 Hours in the rest state

    Pain intensity will be evaluated using an 11-point (0-10) Numeric Pain Rating Scale (NPRS), with higher numbers indicating a higher pain intensity, administered over 48 hours. Time weighted average change from baseline is calculated using the following: time weighted sum of pain intensity differences (SPID) divided by a constant (48 hours) to yield values on the 0-10 NPRS.

    Time frame: 48-hours

Secondary outcomes

  1. the Sum of Pain Intensity Differences in Pain Score Over 6、12、24、 48 、12-24、24-48 Hours under static and moving condition

    Time frame: 48-hours

  2. Time of first use of remedial analgesic medication

    Time frame: 48-hours

  3. Cumulative use of remedial analgesics from 0h to 48h

    Time frame: 48-hours

  4. Participant ' satisfaction score for analgesia treatment

    Time frame: 48-hours

  5. Investigator satisfaction score for analgesia treatment

    Time frame: 48-hours

07

Study locations

1 site
  • Shanghai Jiaotong University School of Medicine,Renji Hospital
    Shanghai, Shanghai 200127, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2022 to primary completion in Oct 2023, 17 months.

Of 41 phase 2/3 interventional studies under Pain, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 30. This study's 17 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 11, 2022
First posted
May 16, 2022
StartActual
May 11, 2022
Primary completionActual
Oct 19, 2023
CompletionActual
Oct 19, 2023
Last update
Dec 26, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 26, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05375305
Responsible party
Sponsor
First posted
May 16, 2022
Start date
May 11, 2022
Primary completion
Oct 19, 2023
Completion
Oct 19, 2023
Last update
Dec 26, 2023

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: SHR8554

Start the discussion